PharmaResearchBio
PharmaResearchBio is the toxin-focused subsidiary of South Korean biotechnology company PharmaResearch. It manufactures and exports the botulinum toxin type A product Re N Tox. This relationship should be read as parent company, manufacturing subsidiary, and product brand—not as interchangeable company names.
PharmaResearchBio obtained Korean approval for Re N Tox 100-unit in February 2024. PharmaResearch announced domestic sales in April 2025, after its toxin subsidiary had already described overseas production and export of 100-unit and 200-unit presentations.
Quick Answers
Section titled “Quick Answers”| Question | Short answer |
|---|---|
| Who makes Re N Tox? | PharmaResearchBio manufactures and exports Re N Tox; PharmaResearch is its parent-company context. |
| Is PharmaResearchBio the same as PharmaResearch? | No. PharmaResearchBio is the toxin-focused subsidiary. PharmaResearch is the wider parent company with a broader regenerative-medicine and aesthetics portfolio. |
| Does Korean approval establish approval elsewhere? | No. Product labels, availability, and approvals remain specific to each market. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Toxin manufacturer | PharmaResearchBio |
| Parent-company context | PharmaResearch 🔗 |
| Toxin product | Re N Tox |
| Product type | Botulinum toxin type A |
| Documented Korean milestone | Re N Tox 100-unit product approval in February 2024; domestic sales announcement in April 2025 |
| Market interpretation | Korean manufacturer and export-product node; no universal label or unit inference |
Portfolio And Market Context
Section titled “Portfolio And Market Context”PharmaResearch presents Re N Tox alongside its broader aesthetics portfolio, which includes Rejuran and other non-toxin products. That commercial adjacency does not make those products clinically related or governed by the same regulatory framework.
The company also announced a patent concerning a polynucleotide-containing long-acting toxin formulation. This is a technology-development claim, not evidence that marketed Re N Tox has a particular duration, safety profile, or clinical advantage.
Comparison Limits
Section titled “Comparison Limits”Re N Tox is a product-specific type A preparation. It should not be treated as unit-equivalent, interchangeable, equally approved, or clinically superior to Botox, Dysport, Xeomin, Jeuveau, Letybo, or another toxin product.